ReviewPhilosophy, ethics, and humanities in medicine : PEHM2025
Emerging, challenges and modernization path of gene privacy in China: from personal privacy to group privacy.
Review in Philosophy, ethics, and humanities in medicine : PEHM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genetic data, which contains human life codes, is the most fundamental privacy of individuals and is therefore protected by the right to privacy. However, given the diverse subjects involved in genetic data, traditional individualistic privacy regulations face challenges in practise, posing a global dilemma on effective gene privacy protection. Over the past three decades, China has seen rapid development in the concepts of privacy and gene privacy. Genetic data is inherently classified as private data, entitled to protection under CCC and CPIPL. China adopts an informed consent model rooted in individualism for gene privacy protection, yet faces triple dilemmas in practice, including inadequate protection for individuals, insufficient safeguards for societal interests, and benefit-sharing imbalances. Going forward, China should first shift its governance philosophy from individualism to group dimension; second, further restrict individuals' self-determination over genetic data; and finally, give full play to its existing organizational structure, public interest litigation system, and the role of groups in safeguarding benefit-sharing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.